Related references
Note: Only part of the references are listed.Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort
Alessia Manni et al.
FRONTIERS IN IMMUNOLOGY (2019)
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
J. William L. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age
Myriam Briner et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Treatment response to dimethyl fumarate is characterized by disproportionate CD8+T cell reduction in MS
Vinzenz Fleischer et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Treatment response to dimethyl fumarate is characterized by disproportionate CD8+T cell reduction in MS
Vinzenz Fleischer et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study
Massimiliano Mirabella et al.
CNS DRUGS (2018)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson et al.
LANCET NEUROLOGY (2018)
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
Ralf Gold et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
Ralf Gold et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
Tomas Kalincik et al.
LANCET NEUROLOGY (2017)
Classifying PML risk with disease modifying therapies
Joseph R. Berger
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
Ann Marie Weideman et al.
FRONTIERS IN NEUROLOGY (2017)
Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation
Katy Wright et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study
A. Miclea et al.
JOURNAL OF NEUROLOGY (2016)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS Patient management considerations
Robert J. Fox et al.
NEUROLOGY-CLINICAL PRACTICE (2016)
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety
Robert J. Fox et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Share Paper
